Clinical trials: Stage IV, NSCLC
Non-small Cell Lung Cancer
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic…
- Trial name
- NCT04656652
- Testing
- DS-1062a, Docetaxel
- Where
- 209 sites in United States, Argentina and 24 more
- Volunteers
- 605 people
- Sponsor
- Daiichi Sankyo
Non-small Cell Lung Cancer
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
This is a phase I/II study of ceritinib and trametinib in Stage IIIB or IV anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC).
- Trial name
- NCT03087448
- Testing
- Ceritinib, Trametinib
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- University of California, San Francisco
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT02520778
- Testing
- Navitoclax, Osimertinib
- Where
- 18 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC Stage IIIB, NSCLC Stage IV
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies
The objective of this study is to assess the efficacy of the combination of Platinum (carboplatin or cisplatin), Pemetrexed, Atezolizumab+/- Bevacizumab if eligible, in stage IIIB/IV non-squamous non-small cell lung cancer…
- Conditions
- NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation, ALK Gene Rearrangement Positive
- Trial name
- GFPC 06-2018 (NCT04042558)
- Testing
- Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab, Carboplatin + Pemetrexed + Atezolizumab
- Where
- 31 sites in France
- Volunteers
- 150 people
- Sponsor
- Centre Francois Baclesse
Non Small Cell Lung Cancer Metastatic
Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma
The aim of this retrospective, multicenter, observational study is to evaluate the potential clinical benefit of adding radiotherapy (administered either concomitantly or sequentially) to immunotherapy in patients with metastatic…
- Trial name
- ARIS (NCT07111104)
- Testing
- Immunotherapy, Radiotherapy
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Hopitaux Prives de Metz, Groupe UNEOS
Carcinoma, Non-Small-Cell Lung
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
To provide expanded access and to evaluate the safety, tolerability and efficacy of afatinib in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Epidermal Growth Factor Receptor (EGFR)…
- Trial name
- NCT01931306
- Testing
- Afatinib
- Where
- 8 sites in South Korea
- Sponsor
- Boehringer Ingelheim
NSCLC Stage IV
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1)…
- Trial name
- NCT06745908
- Testing
- N-803, Tislelizumab, Docetaxel
- Where
- 49 sites in United States, Canada and 1 more
- Volunteers
- 507 people
- Sponsor
- ImmunityBio, Inc.
Lung Cancer, NSCLC
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
- Conditions
- Lung Cancer, NSCLC, NSCLC Stage IV
- Trial name
- TUMORIN (NCT05332925)
- Testing
- Standard of care immune checkpoint inhbitors
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jun Zhang, MD, PhD
Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
This study compares the outcomes and safety of two standard treatment options called microwave ablation and surgical wedge resection in patients with non-small cell lung cancer, sarcoma and colorectal cancer that has spread to…
- Conditions
- Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Sarcoma, Stage I Lung Cancer AJCC v8
- Trial name
- NCT04430725
- Testing
- Computed Tomography with Contrast, Microwave Ablation, Questionnaire Administration
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- M.D. Anderson Cancer Center
Non-small Cell Lung Cancer
Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer
Radiation can induce immunogenic cell death, local release of inflammatory cytokines, and damage associated molecular patterns (DAMPs) resulting in local effects on endothelial cell expression of adhesion receptors, increased…
- Trial name
- SKYROCKET (NCT05034055)
- Testing
- atezolizumab / tiragolumab
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Yonsei University
NSCLC Stage IV
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China.
- Trial name
- NCT04076228
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Kiang Wu Hospital
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma
Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
This phase Ib trial studies the side effects and best dose of telaglenastat hydrochloride when given together with osimertinib in treating patients with stage IV non-small cell lung cancer and a mutation in the EGFR gene.
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03831932
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Elastography
- Where
- 11 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer
Immunotherapy is probably, since the development of therapies targeting EGFR mutations or ALK rearrangement, the most attractive therapeutic perspective in the management of metastatic lung cancer.
- Trial name
- IMMUNO-PREDICT (NCT02827344)
- Testing
- blood sample collection for CTC and MDSC analysis
- Where
- France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Abscopal Effect for Metastatic Non-small Cell Lung Cancer.
Patients with Non-small cell lung cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Radiotherapy, Thymalfasin
- Trial name
- NCT02542930
- Testing
- Radiotherapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Metastatic Nonsmall Cell Lung Cancer
CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]
The goal of this non-interventional study is to emulate the KEYNOTE-189 randomized controlled trial of pembrolizumab for the treatment of metastatic non-small cell lung cancer using real-world, electronic health record data.
- Trial name
- NCT06607393
- Testing
- Pembrolizumab, Pemetrexed, Cisplatin
- Volunteers
- 851 people
- Sponsor
- Aetion, Inc.
Lung Cancer
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether polyglutamate paclitaxel is more effective than docetaxel in treating non-small…
- Trial name
- NCT00054184
- Testing
- docetaxel, paclitaxel poliglumex
- Where
- 35 sites in United States
- Volunteers
- 350 people
- Sponsor
- CTI BioPharma
Non-small Cell Lung Cancer (NSCLC)
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The first treatment is usually chemotherapy, given with another treatment that targets specific proteins on cancer cells.
- Trial name
- NCT07566052
- Testing
- Setidegrasib, Docetaxel
- Where
- 23 sites in United States, China and 1 more
- Volunteers
- 356 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Non Small Cell Lung Cancer
Fecal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced or Metastatic NSCLC
This study aims to investigate the efficacy and safety of fecal microbiota transplantation (FMT) as a treatment for non-small cell lung cancer (NSCLC) patients whose disease has progressed after immune checkpoint inhibitor (ICI)…
- Trial name
- FMT-LUNG (NCT07432984)
- Testing
- Tislelizumab, Fecal Microbiota Transplant(FMT)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Se-Hoon Lee
NSCLC Stage IV, Sex Disorder
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Although many phase III clinical trials evaluate the quality of life as a secondary endpoint, male sexuality remains a neglected topic in oncology research.
- Conditions
- NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
- Trial name
- EROS (NCT06532149)
- Testing
- Alectinib, Brigatinib, Lorlatinib 100 mg
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Carcinoma, Non-Small-Cell Lung
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
- Trial name
- NCT02954991
- Testing
- Glesatinib, Sitravatinib, Mocetinostat
- Where
- 25 sites in United States
- Volunteers
- 161 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.